Gero Discovery

Gero Discovery is a life-science subsidiary associated with Gero that focuses on therapeutics for neurological and neurodegenerative diseases. Publicly available descriptions indicate that the company is developing a small-molecule inhibitor of PFKFB3 aimed at reducing neuronal redox stress and excitotoxicity-driven cell death. Its disclosed lead effort has been described for ischemic stroke and neurodegenerative disorders, with external references also linking the program to CLN7 neuronal ceroid lipofuscinosis/Batten disease research. The company appears to be active, private, and preclinical, with limited standalone public disclosure relative to the parent Gero organization.